This study analysed the efficacy of an angiotensin receptor blocker-based treatment algorithm for achieving goal blood pressure (BP) in patients with stage 1 (systolic BP (SBP) 140-159 mmHg or diastolic BP (DBP) 90-99 mmHg) or stage 2 (SBP X160 mmHg or DBP X100 mmHg) hypertension. In this 24-week, open-label, multicentre study, patients followed a six-step algorithm until goal BP (p130/85 mmHg) was attained. Initially, olmesartan medoxomil 20 mg/day was administered for 4 weeks. The regimen was modified every 4 weeks until goal BP was attained: increase olmesartan medoxomil to 40 mg/day; add hydrochlorothiazide (HCTZ) 12.5 mg/ day; increase HCTZ to 25 mg/day; add amlodipine besylate 5 mg/day; increase amlodipine besylate to 10 mg/day. In patients with stage 1 hypertension, 80% (63/79) and 56% (44/79) achieved BP goals of p140/ 90 mmHg and p130/85 mmHg, respectively, with olmesartan medoxomil monotherapy (94% (74/79) and 89% (70/79) with olmesartan medoxomil/HCTZ double therapy, and 96% (76/79) and 98% (77/79) with addition of amlodipine besylate (triple therapy)). Mean SBP/DBP reductions were 16.7/11.6, 24.8/15.8, and 26.4/16.5 mmHg for mono-, double-, and triple-therapy, respectively. In patients with stage 2 hypertension, 42% (42/100) and 19% (19/100) achieved BP goals of p140/90 mmHg and p130/85 mmHg, respectively, with monotherapy (75% (75/100) and 54% (54/100) with double therapy, and 90% (90/100) and 81% (81/100) with triple-therapy). Mean SBP/DBP reductions in stage 2 patients were 18.4/10.0, 32.7/16.3, and 39.1/19.4 mmHg for mono-, double, and triple therapy, respectively. Overall, most patients with stage 1 or stage 2 hypertension achieved goal BP.
Introduction
The World Health Organization reports that suboptimal blood pressure (BP) control contributes to 62% of cardiovascular disease cases and 49% of ischaemic heart disease cases. 1 In the United States, only 31% of people with hypertension achieve recommended levels of BP control. 2, 3 The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) classifies stage 1 hypertension as systolic BP (SBP) 140-159 mmHg or diastolic BP (DBP) 90-99 mmHg and stage 2 hypertension as SBP X160 or DBP X100 mmHg. JNC 7 recommends that hypertension be treated to reduce BP to o140/90 mmHg for most patients and to o130/80 mmHg for high-risk hypertensives. 2 Reducing BP to 140/90 mmHg provides benefits to the patient with regard to cardiovascular events. It is interesting to speculate that treating hypertension to below 140/90 mmHg may provide further benefits to all patients, regardless of their level of risk.
From a clinical practice perspective, the ability of an agent to reduce BP to recommended BP goals (goal rate) is an important measure of its efficacy. Historically, most studies evaluating the efficacy of antihypertensive agents have concentrated on the mean reductions in BP achieved by a drug, rather than the final absolute BP values. In addition, many studies report the proportion of patients responding to a given therapy (i.e., the 'responder rate'), which is a less clinically practical measurement than goal rates. Responder rates typically include patients attaining an arbitrary, predetermined level of change (usually X10 mmHg reduction from baseline in DBP), as well as those patients achieving a set DBP goal (usually DBP o90 mmHg). Thus, a patient may be counted as a responder and still not have reached goal SBP/DBP. Goal rates, however, are a measure of the proportion of patients who actually achieve combined SBP/DBP goals (e.g., o140/90 mmHg). 2 A recent round table discussion among experts in the field emphasized the point that goal rates are the most clinically relevant measurements, as compared with responder rates, because a patient can be counted as a responder and still have poorly controlled BP. 4 Patients with stage 2 hypertension require greater reductions in BP than patients with stage 1 hypertension, and, thus, combination therapy is usually needed to control BP effectively.
2 JNC 7 suggests that combination therapy may be considered to initiate therapy for patients with stage 2 hypertension and suggests a stepped-care approach for patients with stage 1 hypertension, although a second drug should be added early in the course of therapy for those patients uncontrolled on monotherapy. However, monotherapy alone may be successful for some patients, particularly those with stage 1 hypertension.
The aim of this analysis was to determine the efficacy of an angiotensin receptor blocker (ARB)-based treatment algorithm ( Figure 1 ) for achieving BP goals according to patients' baseline hypertensive severity. The efficacy of the treatment algorithm was analysed separately for those patients with stage 1 or stage 2 hypertension. Results of the efficacy of this treatment algorithm in the combined patient population have been reported previously. 5 
Materials and methods

Study design and patients
This report is based on subgroup analysis derived from a 24-week, multicentre, open-label trial in patients with stage 1 or stage 2 essential hypertension who were X18 years of age. 5 The aim of the original study 5 was to determine the proportion of patients who achieved target BP levels of p140/90 mmHg and p130/85 mmHg, using a stepped-treatment algorithm that started with the ARB olmesartan medoxomil. As soon as patients achieved the target BP goal of p130/85 mmHg, they exited from the study with no further in-study follow-up.
The study consisted of six treatment steps, with each lasting 4 weeks (Figure 1) . Patients who met enrollment criteria following a placebo run-in phase of up to 4 weeks started therapy with 20 mg olmesartan medoxomil once daily. If the target end of study BP (p130/85 mmHg) was not reached, therapy was titrated at 4-week intervals according to the following stepwise algorithm: (1) increase olmesartan medoxomil to 40 mg/day, (2) add 12.5 mg/day hydrochlorothiazide (HCTZ) to the regimen, (3) increase HCTZ to 25 mg/day, (4) add 5 mg/day amlodipine besylate to the regimen, and (5) increase amlodipine besylate to 10 mg/day.
Patients were enrolled if they had a seated DBP (SeDBP) of 90-109 mmHg and a seated SBP (SeSBP) of o200 mmHg at two separate visits during the placebo run-in phase, but only if these two measurements differed by p10 mmHg. The study was performed in accordance with the Declaration of Helsinki and central and local ethical guidelines.
Efficacy and safety assessments
For the purposes of this analysis, patient data were divided into two separate groups according to whether they met JNC 7 criteria for stage 1 or 2 hypertension at baseline. Patients with stage 1
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Step 1 Efficacy with regard to mean BP reductions was calculated for the intent-to-treat (ITT) efficacy cohort (all patients who received at least one dose of initial study medication and had at least one postbaseline BP measurement) using the last observation carried forward method for patients who exited during the study. Goal rate assessments were performed on the evaluable cohort. The evaluable cohort excluded patients from the ITT efficacy cohort who were not given the opportunity to reach target BP for reasons including that they were incorrectly believed to have achieved target BP and exited the study, patient request, protocol violations, investigator error, or being lost to follow-up. Those patients who dropped out of the study for adverse events (AEs), investigator judgment, and high BP were included in the evaluable cohort. BP was measured using a device that prints out BP readings and is thus considered to be free of observer bias.
All AEs reported by patients or observed by investigators and laboratory results were recorded and assessed for seriousness and relation to study drugs. All patients who had at least one dose of study medication were assessed for safety.
Results
Patients with stage 1 hypertension Patient disposition and baseline characteristics. Of the 455 patients screened for the study, 376 were enrolled; 76 patients were excluded during the screening process and three had a placebo run-in visit but did not receive any study medication ( Figure 2 ). Of the 376 patients who were enrolled and entered the placebo run-in phase, 175 were withdrawn because of reasons including mean SeDBP o90 mmHg or 4109 mmHg, patient request, AE, and being lost to follow-up. In all, 230 patients who entered the placebo run-in period had stage 1 hypertension (baseline SBP of 140-159 mmHg or DBP of 90-99 mmHg), and 86 received at least one dose of the initial study medication; these patients constituted the safety cohort. The ITT efficacy cohort included 85 patients, and the evaluable cohort included 79 patients.
The mean age of patients with stage 1 hypertension in the efficacy cohort was 49.4 years (range, Figure 2 Flow of patients through the study. *Patients were removed prior to an amendment to the study protocol that lowered the inclusion criterion for SeDBP from X95 and p109 mmHg to X90 and p109 mmHg. The safety cohort was defined as all patients who received at least one dose of study medication. The efficacy cohort was defined as all patients who received at least one dose of initial study medications and had at least one postbaseline blood pressure (BP) measurement. The evaluable cohort excluded patients from the efficacy cohort who were not given the opportunity to reach target BP for reasons including patient request, protocol violations, investigator error, or being lost to follow-up. SeDBP ¼ seated diastolic BP.
Treatment algorithm for hypertension JM Neutel et al 28-80 years), 69.4% were male, and 70.6% were Caucasian (Table 1) . Patients had a mean 6.8-year history of hypertension, 67.1% had a family history of the disease, and 70.6% had taken antihypertensive medication within the 90 days prior to the study. These medications were discontinued on study entry, and a placebo run-in phase of up to 4 weeks was completed before study medication was administered.
Patients with stage 1 hypertension had a mean baseline BP at treatment initiation of 149.7/ 94.7 mmHg. Analysis of the patients remaining in the study after each treatment step indicated that baseline BPs were not significantly higher in those patients who did not achieve BP goal. For patients with stage 1 hypertension who progressed to week 8 (double therapy with olmesartan medoxomil and HCTZ), the mean baseline BP was 151.9/95.1 mmHg, and the mean baseline BP was 151.1/94.7 mmHg for those who progressed to week 16 (triple therapy with olmesartan medoxomil, HCTZ, and amlodipine besylate). These data suggest that baseline BP is not predictive of the success of treatment. This was also true for patients with stage 2 hypertension (mean baseline BPs of 169.8/98.1, 169.8/98.6, and 171.0/ 99.1 mmHg for patients entering weeks 0, 8, and 16, respectively).
Efficacy. Cumulative goal rates for combined and separate SBP and DBP goals for weeks 8 (monotherapy), 16 (double therapy), and 24 (triple therapy) are given in Table 2 . Goal rates were analysed for the target BPs of p140/90 mmHg and p130/85 mmHg.
At (Figure 3b) . The mean reduction in SeSBP/SeDBP with monotherapy was 16.7/11.6 mmHg; with double therapy it was 24.8/15.8 mmHg, and with triple therapy it was 26.4/16.5 mmHg.
Patients with stage 2 hypertension Patient disposition and baseline characteristics. Of the 376 patients enrolled in the study who entered the placebo run-in phase, 146 had stage 2 hypertension (baseline SBP of X160 mmHg or DBP X100 mmHg) (Figure 2 ). In all, 115 patients received at least one dose of the initial study medication; these patients constituted the safety cohort. The ITT efficacy cohort included 113 patients, and the evaluable cohort included 100 patients.
The mean age at baseline in the stage 2 efficacy cohort was 55.3 years (range, 35-80 years), 61.9% were male, and 76.1% were Caucasian (Table 1) . Patients had a mean 9.4-year history of hypertension, 63.7% had a family history of the disease, and 78.8% had taken antihypertensive medication within the 90 days prior to the study. These medications were discontinued on study entry, and a placebo run-in phase of up to 4 weeks was completed before study medication was administered. Table 1 shows baseline data for both stage 1 and stage 2 populations to facilitate a comparison. However, because this was a retrospective comparison in which each population was characterized by severity of BP, some imbalances in demographic variables, such as age and hypertension history, can be expected. Therefore, applying a statistical test to examine baseline differences between the two populations was determined to be inappropriate. Patients with stage 2 hypertension had a mean baseline BP at treatment initiation of 169.8/98.1 mmHg.
Efficacy. Cumulative goal rates for weeks 8, 16, and 24 are given in Table 2 . With monotherapy, 42.0% (42/100) of patients with stage 2 hypertension achieved the BP goal of p140/90 mmHg, and 19.0%
(19/100) achieved p130/85 mmHg (Figure 4a ). At week 16 (double therapy), 75.0% (75/100) of patients had achieved the BP goal of p140/90 mmHg, and 54.0% (54/100) had achieved p130/85 mmHg. By the end of the 24-week treatment period (triple therapy), 90.0% (90/100) of patients had achieved the BP goal of p140/ 90 mmHg, and 81.0% (81/100) had achieved p130/ 85 mmHg.
As with patients with stage 1 hypertension, the mean reductions in SeSBP and SeDBP increased for patients with stage 2 hypertension as they progressed through the treatment algorithm (Figure 4b (Table 3) .
During active treatment, two patients with stage 1 hypertension discontinued because of an AE. One of these AEs, somnolence, was reported to be definitely related to the study drug (olmesartan medoxomil 20 mg). The other, hyperglycemia, was considered definitely not related to the study drugs. Six patients with stage 2 hypertension discontinued because of an AE. Three of these patients' AEs were judged as possibly related to the study drugs. One patient experienced dyspnea and palpitations, and another experienced chest pain, dyspnea, and tachycardia; these two patients discontinued while taking olmesartan medoxomil 20 mg. The third patient discontinued because of rhinitis while taking olmesartan medoxomil 40 mg/HCTZ 12.5 mg. The other three patients with stage 2 hypertension discontinued because of AEs of bronchitis (judged not related to the study drug), myocardial infarction, or maculopapular rash (both judged possibly related to the study drugs).
Five serious AEs occurred in three patients in the stage 2 population, none of which was judged as related to the study drugs. No serious AEs were reported for patients in the stage 1 population.
Discussion
JNC 7 guidelines recognize that most patients with hypertension will require two or more antihypertensive medications to achieve BP goals and recommend a stepwise approach to treatment. 2 Starting with a renin-angiotensin system blocker is now a common first step in the treatment of hypertension. The addition of a diuretic is the next logical step if hypertension remains uncontrolled, and addition of a calcium channel blocker is appropriate if a third drug is required. Thus, the treatment algorithm used in this study is typical of clinical practice.
Antihypertensive therapy is more likely to be successful when clinically relevant treatment algorithms are used and BP goals are defined. 2, 6 Therefore, goal rates (the percentage of patients achieving specified BP goals), and not responder rates (e.g., SeDBP o90 mmHg or SeDBP reduced by X10 mmHg from baseline), were used as a primary end point in this study. 5 Goal rates may be a more clinically meaningful measure of efficacy than responder rates, as they take into account the actual number of patients achieving the recommended goal BP rather than just an arbitrary reduction in BP.
Analysis of the combined patient population demonstrated the efficacy of this ARB-based treatment algorithm for patients across a wide range of hypertensive severity, allowing 93.3% (167/179) and 87.7% (157/179) of patients to achieve the BP goals of p140/90 mmHg and p130/85 mmHg, respectively. 5 This study demonstrates that the treatment algorithm is effective in patients with either stage 1 or stage 2 hypertension. By the end of the 24-week study, 98 and 96% of the 79 patients with stage 1 hypertension, and 90 and 81% of the 100 patients with stage 2 hypertension achieved BP goals of p140/90 and p130/85 mmHg, respectively. This is substantially better than the 31% control rate reported in national surveys such as the National Health and Nutrition Examination Survey, 3 and suggests that, if physicians are provided with a BP goal and a treatment algorithm, the vast majority of patients with hypertension can be controlled.
An objective of this study was to determine whether a significant percentage of patients with stage 2 hypertension could achieve goal BP safely by following the JNC 7 recommendation that patients with stage 2 hypertension require combination therapy. With this treatment algorithm, patients with stage 2 hypertension achieved considerable reductions in BP, and more than half were able to reach BP goals with double therapy with an ARB and a thiazide diuretic (75% (75/100) and 54% (54/ 100) for the BP goals of p140/90 and p130/ 85 mmHg, respectively). Furthermore, the addition of a calcium channel blocker allowed an additional 15% (15/100) and 27% (27/100) of patients with stage 2 hypertension to achieve BP goals of p140/90 and p130/85 mmHg, respectively, resulting in a total of 90% (90/100) and 81% (81/100) of these patients achieving these goal BPs. The incidence of treatment-emergent AEs was similar in patients with stage 1 or stage 2 hypertension treated with either double or triple therapy, emphasizing that BP goals can be attained in patients with stage 2 hypertension without an increase in the AEs.
Patients with stage 2 hypertension usually require two or more drugs to achieve goal BP. This is reflected in the lower percentage of patients with stage 2 hypertension (as compared with those with stage 1 hypertension) who achieved goal BP with monotherapy. However, with monotherapy, 19% (19/100) of patients with stage 2 hypertension achieved a mean reduction in SeSBP/SeDBP of 44.1/ 24.3 mmHg, allowing them to reach the target BP of p130/85 mmHg, whereas patients with stage 2 hypertension who did not achieve this goal experienced a mean reduction in SeSBP/SeDBP of 13.2/ 7.1 mmHg. The mean reduction from baseline in SeSBP/SeDBP in patients who achieved the BP goal of p140/90 mmHg (42%; 42/100) with monotherapy was 35.7/17.6 mmHg, compared with a mean reduction of 8.2/5.4 mmHg in patients who did not achieve this BP goal. For both BP goals, the mean baseline BPs of the patients who did and did not achieve the goal were similar.
The analysis of this treatment algorithm in patients with stage 2 hypertension suggests that most of these patients will require combination therapy to reach BP goals, in accordance with JNC 7 recommendations.
2 Consequently, treating patients with stage 2 hypertension with combination therapy initially may help more patients achieve goal BP faster. However, the results of this study also suggest that combination therapy may not be required for all patients to achieve goal BP. JNC 7 guidelines recommend stepwise treatment for patients with stage 1 hypertension. 2 Furthermore, the report states that approximately one-third of all patients with hypertension will be able to achieve BP control with monotherapy. Although many patients with stage 1 hypertension were excluded from this study during the placebo runin phase, the data presented suggest that ARB monotherapy can enable a considerable proportion of patients with stage 1 hypertension to achieve BP goals, as more than half of patients with stage 1 hypertension (63/79 and 44/79) achieved the BP goals of p140/90 and p130/85 mmHg, respectively. The data presented in this study also suggest that patients with stage 1 hypertension who are not able to attain goal BP with monotherapy can often do so with the addition of a thiazide diuretic, which allowed approximately 90% of these patients (74/79 and 70/79) to achieve BP goals of p140/90 and p135/85 mmHg, respectively. There was little additional benefit of adding the third drug in this patient population because most patients achieved BP goal with either monotherapy or double therapy.
In the current study, patients dropped out once they reached the target BP of p130/85 mmHg, in accordance with the study protocol, as this was the target BP set by JNC VI for high-risk patients at the time the study was initiated.
7 JNC 7 has since concluded that high-risk patients should achieve a lower target BP of o130/80 mmHg. As a result of the study design, it was not possible to retrospectively analyse the percentage of patients achieving the goal This study employed an objective automated measuring device for obtaining BPs, thereby minimizing observer bias. However, because a large number of patients withdrew from this study prior to receiving active treatment, the possibility that perhaps patients with more difficult-to-control hypertension were excluded cannot be ruled out. In addition, this study was not placebo controlled, and, therefore, some of the high goal rates observed could reflect regression to the mean.
In conclusion, this practice-based, open-label study delineated an antihypertensive treatment algorithm that was well tolerated and allowed most patients to achieve goal BP, irrespective of the severity of hypertension present at baseline. Providing physicians with such a treatment algorithm and establishing BP goals may increase the likelihood of achieving these goals in patients with either stage 1 or stage 2 hypertension.
